Loading...
Loading...
UNCY| Name | Value |
|---|---|
| Revenues | 568.0K |
| Cost of Revenue | 284.0K |
| Gross Profit | 284.0K |
| Operating Expense | 9,261.0K |
| Operating I/L | -9,261.0K |
| Other Income/Expense | -12,264.0K |
| Interest Income | 314.0K |
| Pretax | -21,525.0K |
| Income Tax Expense | 0.0K |
| Net Income/Loss | -21,525.0K |
Unicycive Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for kidney diseases. The company's primary revenue stream comes from the development and commercialization of Renazorb, a treatment for hyperphosphatemia in chronic kidney disease patients, and UNI 494, designed for acute kidney injury treatment.
